Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Ferrannini

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Clinical Science (London, England : 1979)|September 21, 2018
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world dataGiulia Ferrannini, Lars Rydén
European Journal of Preventive Cardiology|November 27, 2019
Risk factor reduction in type 2 diabetes demands a multifactorial approachLars Rydén, Giulia Ferrannini, Linda Mellbin
Heart Failure Clinics|October 10, 2022
SGLT2 Inhibitors in Type 2 Diabetes MellitusGiulia Ferrannini, Gianluigi Savarese, Francesco Cosentino
Diabetes Research and Clinical Practice|April 12, 2021
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibilityGiulia Ferrannini, Gianluigi Savarese, Lars Rydén
Cardiovascular Diabetology|July 5, 2022
Liver function markers predict cardiovascular and renal outcomes in the CANVAS ProgramGiulia Ferrannini, Norman Rosenthal, Michael K Hansen, et al.
Rheumatology (Oxford, England)|August 12, 2022
Antiphospholipid antibodies in patients with calcific aortic valve stenosisOscar Plunde, Elisabet Svenungsson, Giulia Ferrannini, et al.
JCI Insight|December 20, 2024
Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetesEle Ferrannini, Simona Baldi, Maria Tiziana Scozzaro, et al.
Cardiovascular Diabetology|April 29, 2023
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCEGiulia Ferrannini, Carol Pollock, Andrea Natali, et al.
Diabetes Care|July 17, 2015
Energy Balance After Sodium-Glucose Cotransporter 2 InhibitionGiulia Ferrannini, Thomas Hach, Susanne Crowe, et al.
Frontiers in Cardiovascular Medicine|May 29, 2024
The management of heart failure in Sweden-the physician's perspective: a surveyGiulia Ferrannini, Mattia Emanuele Biber, Sam Abdi, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Clinical Science (London, England : 1979)|September 21, 2018
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world dataGiulia Ferrannini, Lars Rydén
European Journal of Preventive Cardiology|November 27, 2019
Risk factor reduction in type 2 diabetes demands a multifactorial approachLars Rydén, Giulia Ferrannini, Linda Mellbin
Heart Failure Clinics|October 10, 2022
SGLT2 Inhibitors in Type 2 Diabetes MellitusGiulia Ferrannini, Gianluigi Savarese, Francesco Cosentino
Diabetes Research and Clinical Practice|April 12, 2021
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibilityGiulia Ferrannini, Gianluigi Savarese, Lars Rydén
Cardiovascular Diabetology|July 5, 2022
Liver function markers predict cardiovascular and renal outcomes in the CANVAS ProgramGiulia Ferrannini, Norman Rosenthal, Michael K Hansen, et al.
Rheumatology (Oxford, England)|August 12, 2022
Antiphospholipid antibodies in patients with calcific aortic valve stenosisOscar Plunde, Elisabet Svenungsson, Giulia Ferrannini, et al.
JCI Insight|December 20, 2024
Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetesEle Ferrannini, Simona Baldi, Maria Tiziana Scozzaro, et al.
Cardiovascular Diabetology|April 29, 2023
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCEGiulia Ferrannini, Carol Pollock, Andrea Natali, et al.
Diabetes Care|July 17, 2015
Energy Balance After Sodium-Glucose Cotransporter 2 InhibitionGiulia Ferrannini, Thomas Hach, Susanne Crowe, et al.
Frontiers in Cardiovascular Medicine|May 29, 2024
The management of heart failure in Sweden-the physician's perspective: a surveyGiulia Ferrannini, Mattia Emanuele Biber, Sam Abdi, et al.
Pageof 5